Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor

Ítems similars

• Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]
  per: Yuming Sun, et al.
  Publicat: (2023-08-01)
• Corrigendum to “Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.” [EClinicalMedicine 37 (2021) 100981]
  per: Vinicius Fontanesi Blum, MD, MSc, et al.
  Publicat: (2021-11-01)
• Corrigendum to “Sex differences in HIV treatment outcomes and adherence by exposure groups among adults in Guangdong, China: A retrospective observational cohort study” [EClinicalMedicine 22 (2020) 100351]
  per: Linghua Li, et al.
  Publicat: (2020-12-01)
• Corrigendum to “Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis” [EClinicalMedicine 55 (2022) 101795]
  per: Zhiwen Fu, et al.
  Publicat: (2023-04-01)
• Impact of national-scale targeted point-of-care symptomatic lateral flow testing on trends in COVID-19 infections and hospitalisations during the second epidemic wave in Austria
  per: Reitzinger, S, et al.
  Publicat: (2023)